IHC - PR Test, Price, Normal Range | Sprint Diagnostics Hyderabad

No, fasting is not required for the IHC - PR test as it uses tissue samples, not blood.

This test is generally recommended after a breast cancer diagnosis to aid in determining the most suitable treatment strategy.

The test measures the presence of progesterone receptors in breast cancer tissue. If present, the cancer might respond to hormone therapy.

This test is typically done once, following a diagnosis of breast cancer. Further testing is decided by your doctor based on your individual treatment response and progress.

Normal results would show no or few progesterone receptors. However, since this test is done on cancer tissue, 'normal' is relative and results should be interpreted by a healthcare provider.

As no specific preparations are needed, you should continue with your regular diet and medications unless advised otherwise by your doctor.

Factors can include age, the stage of the menstrual cycle, and hormone therapy. Genetic factors, which are non-modifiable, can also play a significant role.

Abnormal results should be discussed with your oncologist or the doctor who ordered the test, as they could suggest the need for hormone therapy.

The risks are minimal and are usually related to the biopsy procedure itself, such as discomfort or bruising at the biopsy site.

Yes, hormone therapies and some other medications could potentially affect the result of the test.

No, the IHC - PR test isn't used to diagnose breast cancer, but to guide treatment strategies after a breast cancer diagnosis.

Positive results mean the cancer cells have progesterone receptors and may respond to hormone therapy. Your healthcare provider will discuss suitable treatment options with you.

Yes, the IHC - PR test is usually done alongside an Estrogen Receptor (ER) test and sometimes a HER2 test.

A pathologist usually performs the test in a laboratory setting.

Yes, while breast cancer is more common in women, men can also get it. If a man is diagnosed with breast cancer, the IHC - PR test can be used to guide treatment options.

No, the IHC - PR test can also be used in other types of cancers that may be hormone receptor positive, such as endometrial cancer. However, its most common use is in the context of breast cancer.

While lifestyle changes can generally improve overall health and help in managing many types of illnesses, the results of this test are largely determined by the characteristics of the cancer cells themselves and not directly affected by lifestyle changes.

The test itself is not painful. However, the process of obtaining a tissue biopsy for testing can cause some discomfort.

Yes, the test is essential in predicting how likely the cancer is to respond to hormone therapy. If the test is positive, the cancer is likely to respond to certain hormone therapies.

In sum, the IHC - PR (Progesterone Receptor) Diagnostic Test is a crucial tool that aids in devising the best possible treatment strategy for individuals diagnosed with hormone receptor-positive cancers. Regular dialogue with your healthcare provider is key to understanding the implications of this test, as well as the course of action that would be most beneficial in your unique situation.